Opioid Pharmacology

Correct Answer

B — Synthetic phenylheptylamine full mu opioid receptor agonist with additional N-methyl-D-aspartate receptor antagonist activity

Rationale

Methadone belongs to the phenylheptylamine chemical family and is a full mu opioid receptor agonist. What distinguishes it pharmacologically from most other opioids is its additional N-methyl-D-aspartate receptor antagonist activity, which may contribute to its efficacy in neuropathic pain and to its complex tolerance profile. It also has an unusually long and variable half-life of 24 to 36 hours or longer. A semisynthetic phenanthrene prodrug describes codeine. A synthetic phenylpiperidine partial mu agonist with kappa antagonism describes buprenorphine, which belongs to the phenanthrene family. A naturally occurring phenanthrene pure antagonist describes naloxone.

Correct Answer

D — Synthetic phenylpiperidine full mu opioid receptor agonist that produces the neuroexcitatory metabolite normeperidine

Rationale

Meperidine belongs to the phenylpiperidine chemical family and is a synthetic full mu opioid receptor agonist. Its defining pharmacological liability is the production of normeperidine, a neuroexcitatory metabolite that accumulates with repeated dosing and in renal impairment, lowering the seizure threshold and causing tremors, myoclonus, and seizures. This metabolite profile has led to meperidine falling out of favor in modern pain management. A naturally occurring phenanthrene with N-methyl-D-aspartate antagonism and prolonged half-life describes methadone, which is synthetic and a phenylheptylamine. A semisynthetic phenanthrene partial mu agonist for opioid use disorder describes buprenorphine. A synthetic prodrug requiring cytochrome P450 2D6 conversion describes tramadol.

Correct Answer

A — Semisynthetic phenanthrene full mu opioid receptor agonist with higher oral bioavailability than morphine

Rationale

Oxycodone is a semisynthetic opioid derived from thebaine and belongs to the phenanthrene chemical family. It is a full mu opioid receptor agonist with higher oral bioavailability than morphine because it undergoes less first-pass hepatic metabolism, making it well suited for oral pain management. Its extended-release formulation played a central role in the origins of the opioid epidemic. A synthetic phenylpiperidine producing a neuroexcitatory metabolite describes meperidine (normeperidine). A synthetic phenylheptylamine with N-methyl-D-aspartate antagonism describes methadone. A naturally occurring phenanthrene prodrug requiring enzymatic conversion describes codeine, which depends on cytochrome P450 2D6 to produce morphine.

Correct Answer

C — Semisynthetic phenanthrene full mu opioid receptor agonist derived from morphine, preferred over morphine in patients with renal impairment

Rationale

Hydromorphone is a semisynthetic opioid belonging to the phenanthrene family, derived from morphine. It is a full mu opioid receptor agonist that is approximately five times more potent than morphine by weight. A key clinical advantage is that its metabolites are less pharmacologically active than morphine-6-glucuronide, making it a preferred choice when morphine must be avoided due to renal impairment. A synthetic phenylpiperidine with high lipophilicity and rapid onset describes fentanyl. A synthetic phenylheptylamine with N-methyl-D-aspartate antagonism describes methadone. A naturally occurring phenanthrene prodrug requiring cytochrome P450 2D6 describes codeine.

Correct Answer

A — Synthetic phenylpiperidine full mu opioid receptor agonist available in intravenous, transdermal, and transmucosal formulations

Rationale

Fentanyl is a synthetic opioid belonging to the phenylpiperidine chemical family. It is a full mu opioid receptor agonist with approximately 100 times the potency of morphine. Its high lipophilicity enables rapid onset and supports delivery through multiple routes: intravenous for procedural and intraoperative analgesia, transdermal patch for continuous chronic pain management, and transmucosal and buccal formulations for breakthrough cancer pain. A semisynthetic phenanthrene with active metabolite accumulation in renal failure describes morphine, whose active metabolite morphine-6-glucuronide accumulates. A synthetic phenylheptylamine with N-methyl-D-aspartate antagonism describes methadone. A naturally occurring phenanthrene prodrug requiring cytochrome P450 2D6 describes codeine.

Correct Answer

D — Naturally occurring phenanthrene opioid prodrug that requires cytochrome P450 2D6-mediated hepatic conversion to morphine for its analgesic effect

Rationale

Codeine is a naturally occurring alkaloid from the opium poppy and belongs to the phenanthrene chemical family. It is classified as a prodrug because codeine itself has minimal mu receptor activity — its analgesic effect depends entirely on conversion to morphine by the cytochrome P450 2D6 enzyme in the liver. This prodrug classification has major clinical consequences: patients who are cytochrome P450 2D6 poor metabolizers obtain no analgesia from codeine, while ultrarapid metabolizers generate toxic morphine concentrations at standard doses. A synthetic phenylpiperidine with multiple delivery routes describes fentanyl. A semisynthetic phenanthrene preferred in renal impairment describes hydromorphone. A synthetic phenylheptylamine with N-methyl-D-aspartate antagonism describes methadone.

Correct Answer

C — Oral morphine undergoes extensive first-pass hepatic metabolism, substantially reducing the fraction that reaches systemic circulation

Rationale

After oral ingestion, morphine is absorbed from the gastrointestinal tract and passes through the portal circulation to the liver before reaching systemic circulation. The liver extensively metabolizes morphine during this first pass, so only a fraction of the ingested dose reaches the bloodstream and eventually the brain. Intravenous administration bypasses this first-pass effect entirely, delivering the full dose directly to systemic circulation. This is why the oral dose of morphine required for equivalent analgesia is substantially higher than the intravenous dose — a difference formalized in equianalgesic dosing tables. Oral absorption rate does not cause acute tolerance development. Morphine's mu receptor binding affinity is the same regardless of route of administration. Gastrointestinal mu receptors produce constipation and delayed gastric emptying but do not sequester drug away from central nervous system receptors.

Correct Answer

A — Fentanyl is far more lipophilic than morphine, allowing it to penetrate the blood-brain barrier much more rapidly

Rationale

Lipophilicity is the primary determinant of how rapidly a drug crosses the blood-brain barrier. Fentanyl is substantially more lipophilic than morphine, allowing it to dissolve into and diffuse through the lipid-rich blood-brain barrier membranes within seconds of reaching the brain vasculature. Morphine's comparatively lower lipophilicity means it penetrates the blood-brain barrier more slowly despite reaching equivalent plasma concentrations. This difference in blood-brain barrier penetration rate — not receptor affinity, protein binding, or elimination rate — explains the onset time difference. The speed of brain delivery also explains why intravenous and intranasal opioid administration produces greater euphoria and addiction potential than oral administration of the same drug.

Correct Answer

B — Morphine-6-glucuronide is an active metabolite more potent than morphine itself; it accumulates in renal failure, causing prolonged respiratory depression

Rationale

Morphine is metabolized to two glucuronide conjugates. Morphine-6-glucuronide is pharmacologically active and is actually more potent than morphine at mu receptors. Because both morphine-6-glucuronide and morphine-3-glucuronide are renally excreted, they accumulate in patients with renal impairment. The accumulation of morphine-6-glucuronide produces prolonged and potentially dangerous respiratory depression at doses that would be safe in patients with normal renal function. This is why morphine should be used with caution and at reduced frequency in patients with significant renal dysfunction, and why alternatives such as fentanyl or hydromorphone are often preferred in this setting. A neuroexcitatory metabolite causing seizures describes normeperidine from meperidine. The first-pass effect — not glucuronidation per se — primarily explains the oral-to-intravenous potency difference.

Correct Answer

D — Normeperidine is a neuroexcitatory metabolite that lowers the seizure threshold, causing tremors, myoclonus, and seizures

Rationale

Normeperidine has a profile opposite to that of meperidine itself: instead of opioid receptor-mediated central nervous system depression, normeperidine is neuroexcitatory. It lowers the seizure threshold and causes a progression of symptoms from mild anxiety and tremors through myoclonus to frank seizures as it accumulates. Because normeperidine is renally excreted, accumulation occurs most rapidly in patients with renal impairment and with high or repeated meperidine doses. This toxicity is not reversed by naloxone because it is not mediated by opioid receptors. Meperidine should be avoided in patients with renal impairment and in elderly patients for this reason. Normeperidine is not a mu agonist, does not inhibit cytochrome P450 2D6, and does not activate kappa receptors.

Correct Answer

C — Poor metabolizers cannot convert codeine to morphine, so the prodrug remains inactive and produces no clinically meaningful analgesia

Rationale

Codeine is a prodrug with minimal direct mu receptor activity. Its analgesic effect depends on conversion to morphine by the cytochrome P450 2D6 enzyme. Patients who are cytochrome P450 2D6 poor metabolizers — approximately 7 to 10 percent of white populations — have little or no functional cytochrome P450 2D6 activity and therefore cannot generate morphine from codeine in meaningful amounts. The codeine itself produces no significant analgesia. This may be misidentified as drug-seeking behavior when the patient requests alternative or stronger analgesics, making the underlying pharmacogenomic explanation clinically important. Poor metabolizers do not produce a kappa-antagonizing metabolite, do not accumulate toxic codeine concentrations in a way that causes desensitization, and the relevant metabolic pathway is O-demethylation by cytochrome P450 2D6, not glucuronidation.

Correct Answer

A — The mother converts codeine to morphine at an accelerated rate, producing elevated breast milk morphine concentrations that cause neonatal opioid toxicity

Rationale

Cytochrome P450 2D6 ultrarapid metabolizers have amplified enzyme activity and convert codeine to morphine far more rapidly and completely than normal. This generates higher-than-expected morphine plasma concentrations in the mother, which are then transferred to breast milk. The breastfeeding infant, who has immature drug metabolism and increased blood-brain barrier permeability, is exposed to high morphine concentrations and develops opioid toxicity — manifesting as lethargy, poor feeding, and respiratory depression. Deaths have been reported from this mechanism, leading the United States Food and Drug Administration to issue a black box warning against codeine use in breastfeeding mothers. Normeperidine is a metabolite of meperidine, not codeine. Codeine is converted to morphine, not hydromorphone. Ultrarapid metabolizers convert codeine efficiently rather than accumulating the parent drug.

Correct Answer

B — Fluconazole inhibits cytochrome P450 3A4, slowing methadone metabolism and elevating plasma levels, increasing the risk of QTc prolongation and respiratory depression

Rationale

Methadone is metabolized primarily by the cytochrome P450 3A4 enzyme. Fluconazole is a potent cytochrome P450 3A4 inhibitor. When fluconazole is added to methadone therapy, it slows the hepatic breakdown of methadone, causing plasma methadone levels to rise above the intended therapeutic concentration. Elevated methadone levels increase the risk of two serious adverse effects: QTc interval prolongation (through hERG potassium channel blockade), which can progress to torsades de pointes and ventricular fibrillation, and respiratory depression. Monitoring the electrocardiogram and adjusting methadone doses when cytochrome P450 3A4 inhibitors are added is an important clinical practice point. Fluconazole inhibits, not induces, cytochrome P450 3A4. Fluconazole has no mu receptor activity. Methadone's primary metabolic pathway is cytochrome P450 3A4-mediated N-demethylation, not glucuronidation.

Correct Answer

D — Meperidine inhibits serotonin reuptake; combined with phenelzine-mediated monoamine oxidase inhibition, excess serotonin accumulates, producing serotonin syndrome

Rationale

Meperidine has serotonin reuptake inhibitor activity in addition to its opioid agonist effects. When given to a patient taking a monoamine oxidase inhibitor such as phenelzine, which blocks the enzymatic degradation of serotonin, the combination produces excess synaptic serotonin accumulation. This results in serotonin syndrome: the triad of hyperthermia, neuromuscular abnormalities (agitation, myoclonus, hyperreflexia, rigidity), and autonomic instability (tachycardia, diaphoresis, hyperthermia). The interaction between meperidine and monoamine oxidase inhibitors is considered potentially fatal and is an absolute contraindication. Tramadol shares this risk for the same reason — serotonin reuptake inhibition combined with monoamine oxidase inhibitor use. The other options describe mechanisms that do not apply to this interaction.

Correct Answer

B — Morphine-6-glucuronide, an active metabolite more potent than morphine, accumulates in renal failure and causes prolonged respiratory depression

Rationale

Morphine is hepatically metabolized by glucuronidation to morphine-6-glucuronide and morphine-3-glucuronide. Morphine-6-glucuronide is pharmacologically active and more potent than morphine itself at mu receptors. Both glucuronide metabolites are renally excreted. In patients with renal impairment, morphine-6-glucuronide accumulates progressively, producing opioid effects — including respiratory depression — that outlast the expected duration of the parent drug. The delayed presentation eighteen hours after dosing is characteristic of metabolite accumulation rather than direct morphine toxicity. Morphine itself is primarily hepatically eliminated; the kidney is the primary route for the metabolites, not the parent compound. Normeperidine is a metabolite of meperidine, not morphine, and causes seizures rather than respiratory depression. Renal failure does not substantially alter morphine protein binding in a clinically meaningful way.

Correct Answer

D — The child was a cytochrome P450 2D6 ultrarapid metabolizer who converted codeine to morphine at an accelerated rate, producing toxic morphine concentrations

Rationale

This case reflects the mechanism underlying multiple reported pediatric deaths that led the United States Food and Drug Administration to issue a black box warning against codeine use in children under twelve and in patients undergoing tonsillectomy or adenoidectomy regardless of age. Cytochrome P450 2D6 ultrarapid metabolizers convert codeine to morphine far more rapidly and completely than normal, generating blood morphine concentrations that can reach toxic levels even at standard codeine doses. Children are particularly vulnerable because of their immature hepatic and renal clearance mechanisms and their increased blood-brain barrier permeability. The elevated blood morphine confirmed at autopsy is the pharmacological fingerprint of ultrarapid conversion. Codeine toxicity in this setting is mediated through cytochrome P450 2D6, not cytochrome P450 3A4. Norcodeine is not a recognized toxic metabolite responsible for this outcome.

Correct Answer

A — Heat increased skin blood flow and drug diffusion, accelerating fentanyl absorption from the transdermal depot and raising plasma fentanyl concentrations to toxic levels

Rationale

Transdermal fentanyl works by establishing a subcutaneous drug depot that releases fentanyl at a controlled rate over 72 hours. Heat — from hot tubs, heating pads, electric blankets, or fever — increases peripheral skin blood flow and accelerates diffusion of fentanyl from the depot into the circulation. This can substantially raise plasma fentanyl concentrations above the intended therapeutic level, causing sedation and respiratory depression at a dose that was previously well tolerated. Patients wearing fentanyl patches must be counseled to avoid heat sources. This is a known mechanism of fentanyl overdose and has led to United States Food and Drug Administration safety warnings. The adhesive mechanism is not the relevant pharmacokinetic factor. Cytochrome P450 3A4 is not present in skin in clinically meaningful amounts. Fentanyl does not leach out of the patch into bath water at concentrations that would cause toxicity through skin absorption from the water.

Correct Answer

C — Tolerance developed to oxycodone does not fully transfer to hydromorphone, making the patient relatively more sensitive to the new drug than the equianalgesic calculation predicts

Rationale

Incomplete cross-tolerance is the principle that tolerance developed to one opioid transfers incompletely to a different opioid, even when both act at the same mu receptor. When switching between opioids — a practice called opioid rotation — the patient retains greater sensitivity to the new drug than the equianalgesic table alone would predict. Starting at 25 to 50 percent below the calculated equianalgesic dose and titrating upward is safer than starting at the full calculated dose, which risks respiratory depression because the patient is effectively undertolerant to the new opioid. Hydromorphone does not have a narrower therapeutic index than oxycodone as a class property. Equianalgesic tables do not systematically overestimate hydromorphone potency. Hydromorphone is metabolized primarily by glucuronidation, not cytochrome P450 2D6.